Company Page

Changed Risks for AERIE PHARMACEUTICALS INC (AERI)

We may sell additional debt or equity securities at any time, which may result in dilution to our stockholders and impose restrictions on our business

We have recently begun commercializing Rhopressa

We depend substantially on the success of our FDA-approved product, Rhopressa

, Rocklatan

or any future product candidates in any jurisdiction if regulatory authorities require additional time or studies to assess the safety and efficacy

Borrowings under the credit facility could adversely affect our financial condition and restrict our operating flexibility

are designed to treat patients with open-angle glaucoma or ocular hypertension, and the success or failure of either of them could impact sales of the other or other potential ROCK inhibitor products in the future

and our advanced-stage product candidate, Rocklatan

We have increased the size of our organization, and we may experience difficulties in managing our growth

If we are found in violation of US federal or state “fraud and abuse” laws or other healthcare laws and regulations, we may be required to pay a penalty and/or be suspended from participation in US federal or state healthcare programs, which may adversely affect our business, financial condition and results of operation

If we are unable to establish a direct sales force in jurisdictions outside the United States, our business may be harmed

, our first FDA-approved product, have limited revenue and may never become profitable

or any future product candidates may have undesirable or adverse effects, which may result in the delay, denial or withdrawal of regulatory approval or may require our products to be taken off the market, require them to include safety warnings or otherwise limit their sales after regulatory approval is received

We currently have limited manufacturing capacity and anticipate continued reliance on third-party manufacturers for the development and commercialization of Rhopressa

and we cannot assure you that we will be able to develop our manufacturing plant or manufacture Rhopressa

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management

Our actual or perceived failure to comply with US federal, state, and foreign governmental regulations and other legal obligations related to privacy, data protection and information security could harm our reputation and business

or Rocklatan

Borrowings under the Credit Facility could adversely affect our financial condition and restrict our operating flexibility

ITEM 1A RISK FACTORS

A significant portion of our revenue currently comes from a limited number of distributors, and any decrease in revenue from these distributors could harm our business

in any jurisdiction

We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and disrupt the commercialization of or increase the costs of commercializing Rhopressa

outside the United States or for Rocklatan

The terms of the credit facility may restrict our current and future operations, particularly our ability to respond to changes in our business or to take certain actions

Failure can occur at any stage of clinical development If the clinical trials are unsuccessful, we could be required to abandon development

Our business may be negatively impacted by macroeconomic conditions

Our disclosure controls and procedures and our systems to implement such disclosure controls and procedures may not prevent or detect all errors or acts of fraud

The failure by US Congress to timely approve a budget for the federal government and its agencies, including the FDA, could have a material adverse effect on our business

Any securities litigation could result in substantial damages and may divert management’s time and attention from our business

Changes to the United States tax laws could materially impact our financial position and results of operations

in jurisdictions outside the United States or for Rocklatan

or stop us from commercializing or increase the costs of commercializing Rocklatan

Existing and future legislation may increase the difficulty and cost of commercializing our potential products and may affect the prices we may obtain

If we fail to manage an effective distribution process in the United States or establish an effective distribution process in jurisdictions outside the United States, our business may be adversely affected

and Rocklatan